Daily Stock Analysis, CAPR, Capricor Therapeutics Inc, priceseries

Capricor Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
3.07
Close
2.94
High
3.11
Low
2.94
Previous Close
3.12
Daily Price Gain
-0.18
YTD High
3.37
YTD High Date
Feb 16, 2017
YTD Low
2.12
YTD Low Date
Jan 30, 2017
YTD Price Change
0.39
YTD Gain
15.29%
52 Week High
5.40
52 Week High Date
Jun 16, 2016
52 Week Low
1.91
52 Week Low Date
Mar 2, 2016
52 Week Price Change
0.60
52 Week Gain
25.64%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 23. 2015
4.05
Feb 4. 2015
5.42
8 Trading Days
33.87%
Link
LONG
Mar 13. 2015
7.19
Mar 30. 2015
9.06
11 Trading Days
26.06%
Link
LONG
Apr 18. 2016
3.13
May 3. 2016
3.61
11 Trading Days
15.39%
Link
LONG
Jun 13. 2016
3.41
Jun 27. 2016
3.99
10 Trading Days
17.09%
Link
LONG
Jul 5. 2016
4.26
Jul 6. 2016
4.53
1 Trading Days
6.22%
Link
LONG
Feb 13. 2017
2.82
Feb 23. 2017
2.96
7 Trading Days
5.02%
Link
Company Information
Stock Symbol
CAPR
Exchange
NasdaqCM
Company URL
http://www.capricor.com
Company Phone
(310) 358-3200
CEO
Linda Marbán
Headquarters
California
Business Address
8840 WILSHIRE BLVD, 2ND FLOOR, BEVERLY HILLS, CA 90211
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001133869
About

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases.

Description

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 and enderitide, which are in Phase II clinical trials, as well as CAP-1001, which has completed Phase I clinical trial; and CU-NP and CSps. It is also developing Exosomes for the treatment of cardiovascular and non-cardiovascular diseases. The company was founded in 2005 and is headquartered in Beverly Hills, California.